1
|
Batalha IL, Bernut A, Schiebler M, Ouberai MM, Passemar C, Klapholz C, Kinna S, Michel S, Sader K, Castro-Hartmann P, Renshaw SA, Welland ME, Floto RA. Polymeric nanobiotics as a novel treatment for mycobacterial infections. J Control Release 2019; 314:116-124. [PMID: 31647980 PMCID: PMC6899522 DOI: 10.1016/j.jconrel.2019.10.009] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2019] [Revised: 09/10/2019] [Accepted: 10/03/2019] [Indexed: 12/17/2022]
Abstract
Mycobacterium tuberculosis (Mtb) remains a major challenge to global health, made worse by the spread of multi-drug resistance. Currently, the efficacy and safety of treatment is limited by difficulties in achieving and sustaining adequate tissue antibiotic concentrations while limiting systemic drug exposure to tolerable levels. Here we show that nanoparticles generated from a polymer-antibiotic conjugate (‘nanobiotics’) deliver sustained release of active drug upon hydrolysis in acidic environments, found within Mtb-infected macrophages and granulomas, and can, by encapsulation of a second antibiotic, provide a mechanism of synchronous drug delivery. Nanobiotics are avidly taken up by infected macrophages, enhance killing of intracellular Mtb, and are efficiently delivered to granulomas and extracellular mycobacterial cords in vivo in an infected zebrafish model. We demonstrate that isoniazid (INH)-derived nanobiotics, alone or with additional encapsulation of clofazimine (CFZ), enhance killing of mycobacteria in vitro and in infected zebrafish, supporting the use of nanobiotics for Mtb therapy and indicating that nanoparticles generated from polymer-small molecule conjugates might provide a more general solution to delivering co-ordinated combination chemotherapy.
Collapse
Affiliation(s)
- Iris L Batalha
- Nanoscience Centre, Department of Engineering, University of Cambridge, 11 J.J. Thomson Avenue, Cambridge, CB3 0FF, United Kingdom; Molecular Immunity Unit, Department of Medicine, University of Cambridge, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0QH, United Kingdom
| | - Audrey Bernut
- Dept. of Infection, Immunity & Cardiovascular Disease, Bateson Centre, University of Sheffield, Firth Court, Western Bank, Sheffield, S10 2TN, United Kingdom; Medical School, University of Sheffield, Sheffield, S10 2RX, United Kingdom
| | - Mark Schiebler
- Nanoscience Centre, Department of Engineering, University of Cambridge, 11 J.J. Thomson Avenue, Cambridge, CB3 0FF, United Kingdom; Molecular Immunity Unit, Department of Medicine, University of Cambridge, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0QH, United Kingdom
| | - Myriam M Ouberai
- Nanoscience Centre, Department of Engineering, University of Cambridge, 11 J.J. Thomson Avenue, Cambridge, CB3 0FF, United Kingdom
| | - Charlotte Passemar
- Molecular Immunity Unit, Department of Medicine, University of Cambridge, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0QH, United Kingdom
| | - Catherine Klapholz
- Molecular Immunity Unit, Department of Medicine, University of Cambridge, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0QH, United Kingdom
| | - Sonja Kinna
- Nanoscience Centre, Department of Engineering, University of Cambridge, 11 J.J. Thomson Avenue, Cambridge, CB3 0FF, United Kingdom
| | - Sarah Michel
- Nanoscience Centre, Department of Engineering, University of Cambridge, 11 J.J. Thomson Avenue, Cambridge, CB3 0FF, United Kingdom
| | - Kasim Sader
- Cambridge CryoEM Pharmaceutical Consortium, Thermo Fisher Scientific, Nanoscience Centre, Department of Engineering, University of Cambridge, 11 J.J. Thomson Avenue, Cambridge, CB3 0FF, United Kingdom
| | - Pablo Castro-Hartmann
- Cambridge CryoEM Pharmaceutical Consortium, Thermo Fisher Scientific, Nanoscience Centre, Department of Engineering, University of Cambridge, 11 J.J. Thomson Avenue, Cambridge, CB3 0FF, United Kingdom
| | - Stephen A Renshaw
- Dept. of Infection, Immunity & Cardiovascular Disease, Bateson Centre, University of Sheffield, Firth Court, Western Bank, Sheffield, S10 2TN, United Kingdom; Medical School, University of Sheffield, Sheffield, S10 2RX, United Kingdom
| | - Mark E Welland
- Nanoscience Centre, Department of Engineering, University of Cambridge, 11 J.J. Thomson Avenue, Cambridge, CB3 0FF, United Kingdom.
| | - R Andres Floto
- Molecular Immunity Unit, Department of Medicine, University of Cambridge, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0QH, United Kingdom; Cambridge Centre for Lung Infection, Royal Papworth Hospital, Cambridge, CB23 3RE, United Kingdom.
| |
Collapse
|
2
|
Schiebler M, Brown K, Hegyi K, Newton SM, Renna M, Hepburn L, Klapholz C, Coulter S, Obregón-Henao A, Henao Tamayo M, Basaraba R, Kampmann B, Henry KM, Burgon J, Renshaw SA, Fleming A, Kay RR, Anderson KE, Hawkins PT, Ordway DJ, Rubinsztein DC, Floto RA. Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion. EMBO Mol Med 2015; 7:127-39. [PMID: 25535254 PMCID: PMC4328644 DOI: 10.15252/emmm.201404137] [Citation(s) in RCA: 118] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Mycobacterium tuberculosis (MTB) remains a major challenge to global health made worse by the spread of multidrug resistance. We therefore examined whether stimulating intracellular killing of mycobacteria through pharmacological enhancement of macroautophagy might provide a novel therapeutic strategy. Despite the resistance of MTB to killing by basal autophagy, cell-based screening of FDA-approved drugs revealed two anticonvulsants, carbamazepine and valproic acid, that were able to stimulate autophagic killing of intracellular M. tuberculosis within primary human macrophages at concentrations achievable in humans. Using a zebrafish model, we show that carbamazepine can stimulate autophagy in vivo and enhance clearance of M. marinum, while in mice infected with a highly virulent multidrug-resistant MTB strain, carbamazepine treatment reduced bacterial burden, improved lung pathology and stimulated adaptive immunity. We show that carbamazepine induces antimicrobial autophagy through a novel, evolutionarily conserved, mTOR-independent pathway controlled by cellular depletion of myo-inositol. While strain-specific differences in susceptibility to in vivo carbamazepine treatment may exist, autophagy enhancement by repurposed drugs provides an easily implementable potential therapy for the treatment of multidrug-resistant mycobacterial infection.
Collapse
Affiliation(s)
- Mark Schiebler
- Department of Medicine, Cambridge Institute for Medical Research University of Cambridge, Cambridge, UK
| | - Karen Brown
- Department of Medicine, Cambridge Institute for Medical Research University of Cambridge, Cambridge, UK Cambridge Centre for Lung Infection, Papworth Hospital, Cambridge, UK
| | - Krisztina Hegyi
- Department of Medicine, Cambridge Institute for Medical Research University of Cambridge, Cambridge, UK
| | - Sandra M Newton
- Department of Paediatric Infectious Diseases and Allergy, Imperial College London, London, UK
| | - Maurizio Renna
- Department of Medical Genetics, Cambridge Institute for Medical Research University of Cambridge, Cambridge, UK
| | - Lucy Hepburn
- Department of Medicine, Cambridge Institute for Medical Research University of Cambridge, Cambridge, UK
| | - Catherine Klapholz
- Department of Medicine, Cambridge Institute for Medical Research University of Cambridge, Cambridge, UK
| | - Sarah Coulter
- Department of Medicine, Cambridge Institute for Medical Research University of Cambridge, Cambridge, UK
| | - Andres Obregón-Henao
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA
| | - Marcela Henao Tamayo
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA
| | - Randall Basaraba
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA
| | - Beate Kampmann
- Department of Paediatric Infectious Diseases and Allergy, Imperial College London, London, UK
| | - Katherine M Henry
- Department of Infection and Immunity, University of Sheffield Western Bank, Sheffield, UK
| | - Joseph Burgon
- Department of Infection and Immunity, University of Sheffield Western Bank, Sheffield, UK
| | - Stephen A Renshaw
- Department of Infection and Immunity, University of Sheffield Western Bank, Sheffield, UK
| | - Angeleen Fleming
- Department of Medical Genetics, Cambridge Institute for Medical Research University of Cambridge, Cambridge, UK
| | - Robert R Kay
- MRC Laboratory of Molecular Biology, Cambridge, UK
| | - Karen E Anderson
- The Inositide Laboratory, Babraham Institute Babraham Research Campus, Cambridge, UK
| | - Phillip T Hawkins
- The Inositide Laboratory, Babraham Institute Babraham Research Campus, Cambridge, UK
| | - Diane J Ordway
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA
| | - David C Rubinsztein
- Department of Medical Genetics, Cambridge Institute for Medical Research University of Cambridge, Cambridge, UK
| | - Rodrigo Andres Floto
- Department of Medicine, Cambridge Institute for Medical Research University of Cambridge, Cambridge, UK Cambridge Centre for Lung Infection, Papworth Hospital, Cambridge, UK
| |
Collapse
|
3
|
Hepburn L, Prajsnar TK, Klapholz C, Moreno P, Loynes CA, Ogryzko NV, Brown K, Schiebler M, Hegyi K, Antrobus R, Hammond KL, Connolly J, Ochoa B, Bryant C, Otto M, Surewaard B, Seneviratne SL, Grogono DM, Cachat J, Ny T, Kaser A, Török ME, Peacock SJ, Holden M, Blundell T, Wang L, Ligoxygakis P, Minichiello L, Woods CG, Foster SJ, Renshaw SA, Floto RA. Innate immunity. A Spaetzle-like role for nerve growth factor β in vertebrate immunity to Staphylococcus aureus. Science 2014; 346:641-646. [PMID: 25359976 DOI: 10.1126/science.1258705] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Many key components of innate immunity to infection are shared between Drosophila and humans. However, the fly Toll ligand Spaetzle is not thought to have a vertebrate equivalent. We have found that the structurally related cystine-knot protein, nerve growth factor β (NGFβ), plays an unexpected Spaetzle-like role in immunity to Staphylococcus aureus infection in chordates. Deleterious mutations of either human NGFβ or its high-affinity receptor tropomyosin-related kinase receptor A (TRKA) were associated with severe S. aureus infections. NGFβ was released by macrophages in response to S. aureus exoproteins through activation of the NOD-like receptors NLRP3 and NLRP4 and enhanced phagocytosis and superoxide-dependent killing, stimulated proinflammatory cytokine production, and promoted calcium-dependent neutrophil recruitment. TrkA knockdown in zebrafish increased susceptibility to S. aureus infection, confirming an evolutionarily conserved role for NGFβ-TRKA signaling in pathogen-specific host immunity.
Collapse
Affiliation(s)
- Lucy Hepburn
- Cambridge Institute for Medical Research, University of Cambridge, UK.,Department of Medicine, University of Cambridge, UK
| | - Tomasz K Prajsnar
- Krebs Institute, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK.,Department of Molecular Biology and Biotechnology, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK.,Bateson Centre, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK
| | - Catherine Klapholz
- Cambridge Institute for Medical Research, University of Cambridge, UK.,Department of Medicine, University of Cambridge, UK
| | - Pablo Moreno
- Cambridge Institute for Medical Research, University of Cambridge, UK
| | - Catherine A Loynes
- Bateson Centre, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK.,Department of Infection and Immunity, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK
| | - Nikolay V Ogryzko
- Bateson Centre, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK
| | - Karen Brown
- Cambridge Institute for Medical Research, University of Cambridge, UK.,Department of Medicine, University of Cambridge, UK.,Cambridge Centre for Lung Infection, Papworth Hospital, Cambridge, UK
| | - Mark Schiebler
- Cambridge Institute for Medical Research, University of Cambridge, UK.,Department of Medicine, University of Cambridge, UK
| | - Krisztina Hegyi
- Cambridge Institute for Medical Research, University of Cambridge, UK.,Department of Medicine, University of Cambridge, UK
| | - Robin Antrobus
- Cambridge Institute for Medical Research, University of Cambridge, UK
| | - Katherine L Hammond
- Bateson Centre, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK.,Department of Infection and Immunity, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK
| | - John Connolly
- Krebs Institute, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK.,Department of Molecular Biology and Biotechnology, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK
| | | | - Clare Bryant
- Department of Veterinary Medicine, University of Cambridge, UK
| | - Michael Otto
- Laboratory of Human Bacterial Pathogenesis NIAID, NIH, Bethesda USA
| | - Bas Surewaard
- Dept of Medical Microbiology, University Medical Centre, Utrecht, Netherlands
| | | | - Dorothy M Grogono
- Department of Medicine, University of Cambridge, UK.,Cambridge Centre for Lung Infection, Papworth Hospital, Cambridge, UK
| | - Julien Cachat
- Dept. of Pathology and Immunology, Geneva University, Switzerland
| | - Tor Ny
- Dept. of Medical Biochemistry and Biophysics, Umea University, Sweden
| | - Arthur Kaser
- Department of Medicine, University of Cambridge, UK
| | | | - Sharon J Peacock
- Department of Medicine, University of Cambridge, UK.,Wellcome Trust Sanger Institute, Hinxton, UK
| | | | - Tom Blundell
- Department of Biochemistry, University of Cambridge, UK
| | - Lihui Wang
- Biochemistry Department, Oxford University. UK
| | | | | | - C Geoff Woods
- Cambridge Institute for Medical Research, University of Cambridge, UK.,Department of Medical Genetics, University of Cambridge, UK
| | - Simon J Foster
- Krebs Institute, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK.,Department of Molecular Biology and Biotechnology, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK
| | - Stephen A Renshaw
- Krebs Institute, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK.,Bateson Centre, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK.,Department of Infection and Immunity, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK
| | - R Andres Floto
- Cambridge Institute for Medical Research, University of Cambridge, UK.,Department of Medicine, University of Cambridge, UK.,Cambridge Centre for Lung Infection, Papworth Hospital, Cambridge, UK
| |
Collapse
|